Compare ADSE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADSE | ALLO |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 539.4M |
| IPO Year | N/A | 2018 |
| Metric | ADSE | ALLO |
|---|---|---|
| Price | $10.46 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.36 |
| AVG Volume (30 Days) | 3.7K | ★ 4.5M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $219.58 | N/A |
| Revenue Next Year | N/A | $141,204.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.89 | $0.86 |
| 52 Week High | $15.18 | $2.80 |
| Indicator | ADSE | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 57.05 |
| Support Level | $9.55 | $1.01 |
| Resistance Level | $12.79 | $2.80 |
| Average True Range (ATR) | 0.78 | 0.19 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 15.29 | 48.33 |
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.